Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 3/20 | 0.36 |
| ▸ | CCNE1 | P24864 | 4/20 | 0.35 |
| ▸ | CDK2 | P24941 | 4/20 | 0.35 |
| ▸ | BRD4 | O60885 | 7/20 | 0.33 |
| ▸ | MAPK7 | Q13164 | 7/20 | 0.33 |
| ▸ | RORC | P51449 | 5/20 | 0.33 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.32 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.32 |
| ▸ | BRD2 | P25440 | 1/20 | 0.32 |
| ▸ | EP300 | Q09472 | 1/20 | 0.32 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.32 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.32 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23317068 | 0.86 | MAPK1 (0.36) | CCNE1CDK2RORC | |
| SCHEMBL29758598 | 0.86 | MAPK1 (0.36) | CCNE1CDK2RORC | |
| SCHEMBL23304715 | 0.84 | IRAK4 (0.32) | — | |
| SCHEMBL23305171 | 0.84 | — | — | |
| SCHEMBL23304876 | 0.84 | HPGDS (0.32) | — | |
| SCHEMBL30200940 | 0.84 | CCNC (0.30) | — | |
| SCHEMBL23304778 | 0.84 | CCNC (0.30) | — | |
| SCHEMBL23305557 | 0.82 | ACACB (0.34) | — | |
| SCHEMBL23305305 | 0.82 | — | — | |
| SCHEMBL23304822 | 0.81 | IRAK4 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230060003-A1 | SPIROCYCLIC O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLUCOPYRANOSIDASE INHIBITORS | BIOGEN MA INC. | 2023-02-23 | — | — | US | disclosed |
| WO-2021086966-A1 | SPIROCYCLIC O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLUCOPYRANOSIDASE INHIBITORS | BIOGEN MA INC. (US) | 2021-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230060003-A1 | SPIROCYCLIC O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLUCOPYRANOSIDASE INHIBITORS | MAN2A1, MAN2B2, ST6GAL1 | HCAR3 3709/4885CCNE1 331/4885CDK2 501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.